PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |

capecitabine

  • capecitabine did not meet the criteria of being an inhibitor or inducer of CYP2C9.
  • CYP2C9
    Criteria not metcapecitabine [1]
    itraconazole [2]

    Footnotes and References

    1.Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. Journal of Clinical Oncology 2005; 23: 4719-25.[PubMed]
    2.Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. British Journal of Clinical Pharmacology 1998; 46: 49-53.[PubMed]
    Disclaimer
    WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.